Search Medical Condition
Please enter condition
Please choose location

Braine l'Alleud, Belgium Clinical Trials

A listing of Braine l'Alleud, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (32) clinical trials

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

In the majority of European countries, the primary management of chronic heart failure patients is performed by General Practitioners in collaboration with cardiologists (specialists). Previous studies have shown that many patients suffering from CHF do not receive optimal pharmacological and/or device treatment for their disease. An increase in natriuretic peptides ...

Phase

4.3 miles

Learn More »

Prevention of Antibiotic-Associated Diarrhoea With Prolardii

Prolardii is a synbiotic (prebiotic and probiotic) formulation including 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium, a plant that can contribute to the ...

Phase N/A

5.75 miles

Learn More »

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis

This is a prospective, observational, cohort study to collect data on adult participants who have a confirmed diagnosis of psoriatic arthritis (PsA) and are starting either STELARA or a new TNFi as a new therapy in a first, second, or third line of biologic disease-modifying antirheumatic drug (bDMARD) therapy. Approximately ...

Phase N/A

6.48 miles

Learn More »

A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla (Apremilast) in Belgium

Patient care will follow routine clinical practice, involving regular follow-up visits, without any mandatory visit. In daily practice, patients are usually seen by their treating rheumatologist every 3 months. In this study, patients will be followed-up for a least 6 months and at most 18 months after apremilast treatment initiation. ...

Phase N/A

6.48 miles

Learn More »

Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer

A majority of cervical carcinomas are caused by an uncontrolled, persistent infection with high risk Human Papilloma Virus (HPV). ISA101/ISA101b is a novel therapeutic synthetic long peptide (SLP) vaccine targeting HPV16 which is being developed and has shown efficacy in patients with high-grade premalignant vulvar lesions caused by HPV with ...

Phase

7.33 miles

Learn More »